



Published in final edited form as:

Am J Med Genet A. 2014 September ; 0(9): 2206–2211. doi:10.1002/ajmg.a.36624.

Association Between Macroorchidism and Intelligence in *FMR1* Premutation Carriers

Reymundo Lozano^{1,2}, Scott Summers^{1,3}, Cristina Lozano¹, Yi Mu⁴, David Hessler^{1,3}, Danh Nguyen⁵, Flora Tassone^{1,6}, and Randi Hagerman^{1,2}

¹Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Medical Center, Sacramento, California

²Department of Pediatrics, UC Davis Medical Center, Sacramento, California

³Department of Psychiatry and Behavioral Sciences, UC Davis Medical Center, Sacramento, California

⁴Department of Public Health Sciences, Division of Biostatistics, UC Davis

⁵UC Irvine Institute for Clinical and Translational Science, Irvine, CA

⁶Department of Biochemistry and Molecular Medicine, UC Davis Medical Center, Sacramento, California

Abstract

Characteristics of fragile X syndrome include macroorchidism and intellectual disability, which are associated with decreased FMRP levels. FMRP is highly expressed in many tissues, but primarily in the brain and testis. The relationship between these two characteristics has not previously been studied in the premutation or carrier state. To examine this among premutation carriers and a possible association with IQ, we evaluated macroorchidism status among 213 males including 142 premutation carriers and 71 controls. The prevalence of macroorchidism among premutation carriers was 32.4% (46 out of 142), and 5.6% among controls (4 out of 71, $P < 0.0001$). Among premutation carriers, the age-adjusted odds ratio (OR) of macroorchidism was significantly increased with increasing *FMR1* mRNA (OR 1.84, 95% confidence interval [CI] 1.04–3.25; $P 0.035$). With respect to the association between macroorchidism and IQ, after adjustment for number of CGG repeats and age, premutation carriers with macroorchidism had lower verbal IQ (104.67 ± 15.86 , $P 0.0152$) and full scale IQ (102.98 ± 15.78 , $P 0.0227$) than premutation carriers without macroorchidism (verbal IQ 112.38 ± 14.14 , full scale IQ 110.24 ± 14.21). Similar associations were observed for both verbal IQ ($P 0.034$) and full scale IQ ($P 0.039$) after being adjusted for age and *FMR1* mRNA. These preliminary data support a correlation between macroorchidism and lower verbal and full scale IQ in a relevant proportion of premutation carrier males. Whether this is due to higher levels of *FMR1* mRNA or to lower FMRP levels it remains to be established.

Keywords

premutation; *FMRI* gene; premutation; macroorchidism and biomarker

INTRODUCTION

Fragile X syndrome (FXS) and Fragile X-associated disorders (FADs) are related to mutations in the Fragile X Mental Retardation 1 gene (*FMRI*). In the normal range, there are 5 to 44 CGG repeats in the 5' untranslated region of *FMRI*. The Fragile X mutation occurs in two forms, the premutation with 55–200 CGG repeats and the full mutation with more than 200 repeats. There is also a gray zone for individuals with 45–54 CGG repeats who may or may not present with premutation manifestations [Loesch et. al., 2011; Sullivan et. al., 2011]. The prevalence of the full mutation is approximately 1 in 4000 males and 1 in 8000 females [Coffee et. al., 2009; Crawford and et. al., 2001]. The average IQ of an adult male with FXS is approximately 40, but those with a lack or partial lack of methylation (methylation mosaicism) or those who have size mosaicism have an average IQ in the 60s [Merenstein et. al., 1996]. Approximately 15% are high functioning with an IQ greater than 70. Most girls with FXS, on the other hand, have an IQ above 70, although 25% have intellectual disability. The X-activation ratio, meaning the percentage of cells with the normal X chromosome active, correlates with the overall IQ in girls with FXS [Hagerman and Hagerman, 2002].

In the full mutation, or occasionally the higher end of the premutation range, methylation prevents transcription of *FMR1* mRNA and the consequent *FMRI* protein (FMRP) deficit results in intellectual disability and other physical features seen in FXS. Conversely, the more typical finding in the premutation range is very high levels of *FMRI* mRNA leading to RNA toxicity [Hagerman, 2013; Tassone et. al., 2000]. The number of CGG repeats has been shown to directly correlate with the amount of *FMR1* mRNA [Ludwig et. al., 2014]. Clinically, this RNA toxicity can lead to psychiatric difficulties in childhood including attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (ASD), shyness and social anxiety [Chonchaiya et. al., 2012]. ADHD and ASD can persist into adulthood, but depression and anxiety are the most common psychiatric disorders of adults with the premutation [Bourgeois et. al., 2011].

The premutation is also the most common genetic cause of primary ovarian insufficiency, defined as cessation of menses before age 40, and occurs in approximately 20% of female carriers [Sullivan et. al., 2011]. Neurological problems are common in adults with the premutation including neuropathy, tremor, ataxia and cognitive decline; these are the primary symptoms of the fragile X-associated tremor ataxia syndrome (FXTAS). The FXTAS incidence is approximately 40% of male carriers and 16% of female carriers. Females carriers with FXTAS have milder symptoms than males and rarely have dementia [Hagerman, 2013]. The prevalence of the premutation in the general population is approximately 1 in 200 females and 1 in 450 males [Tassone et. al., 2012].

In children with the premutation, IQ scores were found to be lower than in controls, but not to a statistically significant degree [Myers et. al., 2001]. However, children and young adults

with the premutation have a higher incidence of ADHD and showed executive function deficits [Cornish et. al., 2009; Grigsby et. al., 2008; Moore et. al., 2004a; Moore et. al., 2004b], which can impact cognitive function and IQ scores.

FMRI is highly expressed in the brain and testis in the normal population and the RNA toxicity of FXTAS is associated with the formation of inclusions in neurons [Leehey et. al., 2008; Tassone et. al., 2007] and testicular Leydig cells in carriers [Gokden et. al., 2009; Greco et. al., 2007; Hunsaker et. al., 2011]. Macroorchidism is observed in almost all individuals with FXS and anecdotally in premutation carriers. The present study specifically characterizes the frequency of macroorchidism in premutation carriers and its association with cognitive abilities and molecular measures.

MATERIALS AND METHODS

Data Collection

Data relevant to this study were collected from 218 male research subjects with Tanner Stage IV pubertal development; macroorchidism was defined as a testicular volume >30 mls. This included 46 premutation carriers with macroorchidism and a mean age of 56.35 years, 96 carriers without macroorchidism with a mean age of 57.39 years and 67 control subjects with a mean age 45.36 years. Each subject had been actively recruited to the UC Davis MIND Institute for participation in studies that all required a medical history and physical examination. All subjects signed an informed consent document as part of IRB project approval. Each physical exam sheet completed by a physician indicated the presence or absence of macroorchidism in the subject. Most subjects (70% of controls and 98% of premutation carriers) also had a quantitative bilateral measurement of testicular volume recorded. The average testicular volume after puberty is 18 cm³ (ml) with a normal size ranging from 12 cm³ to 24 cm³ [Goodman and Gorlin, 1983; Meschede et. al., 1995; Zachmann et. al., 1974]. Macroorchidism was defined as a testicular volume greater than 30cm³. Testicular volume was measured by a Prader orchidometer, which in previous correlates well with the gold standard of ultrasound measurements [Paltiel et. al., 2002]. All subjects included in this study also completed the Wechsler Adult Intelligence Scale-IV or III [Wechsler 1997].

Molecular Status

Molecular measure of the CGG trinucleotide expansion was used to separate controls from premutation carriers. Analysis of blood drawn from research subjects was completed using an Alpha Innotech FluorChem 8800 Image Detection System (Alpha Innotech Co., San Leandro, CA). The specific protocol has been previously outlined [Saluto et. al., 2005; Tassone et. al., 2000; Tassone et. al., 2004]. Repeat sizes between 55 and 200 inclusive were considered premutation carriers. Repeat numbers under 45 were treated as controls. Subjects in the full mutation range (above 200 CGG repeats) or in the gray zone (45–55 repeats) were excluded from this study. Subjects displaying mosaicism, regardless of CGG repeat number, were also excluded. Serum *FMRI* mRNA levels were collected and examined when available in a method described previously [Tassone et. al., 2000].

Statistical Analysis

Descriptive statistical analysis was based on Chi-square test for categorical variables and the analysis of variance (ANOVA) for continuous variables. Logistic regression was used to compare the age-adjusted odds ratio of macroorchidism status among premutation carriers, as a function of molecular variants, CGG and *FMR1* mRNA. Comparisons of verbal IQ, performance IQ, and full scale IQ across three groups (premutation carriers with macroorchidism, premutation carriers without macroorchidism and controls without macroorchidism) were performed using the analysis of covariance (ANCOVA). All statistical analysis was conducted in SAS version 9.2.

RESULTS

Characteristics of study subjects

The initial cohort (N=213) comprised 142 premutation carriers and 71 controls. The prevalence of macroorchidism among premutation carriers was 32.4% (46 out of 142) and 5.6% among controls (4 out of 71, $P < 0.0001$). After excluding the four controls with macroorchidism, the final analysis cohort (N=209) included 46 premutation subjects with macroorchidism (group A); 96 premutation subjects without macroorchidism (group B); and 67 control subjects without macroorchidism (group C). Table I summarizes the study participant characteristics and unadjusted descriptive analysis results across three groups. Among premutation carriers, age and CGG showed no significant difference with regard to macroorchidism status (A vs. B), but *FMR1* mRNA in premutation carriers with macroorchidism (Mean 3.24, SD1.26) was significantly higher than premutation carriers without macroorchidism (Mean 2.76, SD 0.82, $P 0.0021$). Verbal IQ, performance IQ, and full scale IQ of both group A and group B were significantly different from group C (< 0.0001).

Macroorchidism in premutation carriers and association with *FMR1* mRNA and number of CGG repeats

The likelihood (odds) of macroorchidism, adjusted for age, was significantly associated with *FMR1* mRNA; given 1 unit increase in *FMR1* mRNA (i.e., about 0.9 SD), the odds ratio of macroorchidism was 1.84 (95% confidence interval [CI] 1.04–3.25; $P 0.035$). The age-adjusted odds ratio of macroorchidism was not associated with CGG repeat number (Table II).

Associated between macroorchidism and IQ

Table IIIa summarizes Verbal IQ, Performance IQ, and Full scale IQ across three groups, adjusted for age and number of CGG repeats. Verbal IQ measurements among premutation carriers with macroorchidism (Group A: Mean 104.67, SD 15.86) were lower than premutation carriers without macroorchidism (Group B: Mean 112.38, SD 14.14, $P 0.0152$). Full Scale IQ measurements among premutation carriers with macroorchidism (Group A: Mean 102.98, SD 15.78) were also lower than premutation carriers without macroorchidism (Group B: Mean 110.24, SD 14.21, $P 0.0227$).

In Table IIIb, after adjusting for age and *FMRI* mRNA levels, both verbal IQ (P 0.034) and full scale IQ (P 0.0399) among premutation carriers with macroorchidism (Group A) was lower than premutation carriers without macroorchidism (Group B). Premutation carriers with macroorchidism (Group A) also had lower full scale IQ (P 0.0363) than controls without macroorchidism (Group C). The results were not statistically significant at level 0.05 after Bonferroni adjustment for multiple comparisons (Table IIIb).

DISCUSSION

Testicular examination can be important in the diagnosis of genetic conditions. There are over 20 genetic syndromes associated with variations in testicular size including Clark-Baraitser syndrome [Mendicino et. al., 2005], aspartylglucosaminuria [Arvio and Arvio 2002], Atkin-Flaitz syndrome [Atkin et. al., 1985], McCune-Albright syndrome [Wasniewska et. al., 2006] and X-linked intellectual disability syndromes. According to the Online Mendelian Inheritance in Man database (omim.org), about two thirds of syndromes associated with macroorchidism are also associated with intellectual disability and roughly one third have an X-linked inheritance pattern. Testicular volume differences can help clarify diagnoses. For example, testicular volume is used to separate Marfan and Klinefelter syndromes. Individuals with both present with grossly similar phenotypes including a tall and thin body habitus, but a hallmark of Klinefelter syndrome is reduced testicular size, whereas individuals with Marfan syndrome typically do not have this finding [Marcell and Ellen 2012].

On the other side of the size spectrum, individuals with FXS often present with signs of a connective tissue disorder including joint laxity [Davids et. al., 1990], mitral valve prolapse and aortic dilation [Sreeram et. al., 1989] similar to individuals with Marfan syndrome. However, it is well known that most of the patients with FXS actually display enlarged testicular volume among other associated signs and symptoms that can help separate it diagnostically [Butler et. al., 1993; Crabbe et. al., 1993]. One of the new findings in this study is that differential diagnosis of macroorchidism should potentially be expanded from FXS to also include the premutation form of the *FMRI* gene. The relative risk of macroorchidism in the premutation population was 5.75 times that of control (5.6%; P<0.001) and was seen in nearly a third of carriers. This could be very useful as the clinical diagnosis of a premutation male carrier is often challenging because most do not present with the typical features of FXS. Early diagnosis of premutation carriers can help patients begin to screen for and treat some of the associated features, such as, anxiety, hypertension, hypothyroidism and migraines which in turn may help to decrease the changes of developing FXTAS [Hagerman and Hagerman 2013].

It is known that the IQ is lower in premutation carriers when compared with the general population [Fisch 2006], however, our study adds that among premutation carriers, macroorchidism was significantly associated with lower verbal IQ after adjustment for age and number of CGG repeats (Supplementary Table Ia, Supplementary Figure 1 in supporting information online). The verbal distinction seen here may relate to some of the verbal deficits seen in FXS, particularly those suffering from autism. Individuals with the premutation and macroorchidism had significantly higher levels of *FMRI* mRNA (OR 1.84,

95% CI 1.04–3.25; P 0.035), but macroorchidism was not strongly associated with number of CGG repeats. While in the full mutation *FMR1* mRNA is decreased and FMRP is absent or significantly decreased, in the premutation the elevated *FMR1* mRNA level is associated with lower levels of FMRP. Often FMRP is also lower in those with a higher number of CGG repeats at the upper end of the premutation range [Brouwer et. al., 2009; Pretto et. al., 2014]. This suggests that higher levels of mRNA may be associated with FMRP deficits in premutation carriers, which could be the cause of both the lower IQ and macroorchidism seen here.

We were not able to carry out FMRP studies in this investigation, however new techniques are being developed to more easily study FMRP levels [LaFauci et. al., 2013; Schutzius et. al., 2013]. There is significant variability of FMRP levels even in the general population [Iwahashi et. al., 2009] and the level of FMRP has been recently associated with cognitive abilities and frontal dysfunction in the general population [Wang et. al., 2013]. This will likely be an area for future research.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was funded with support from the following grants: National Institute of Health HD036071, AG032115, MH078041, UL1 TR000153 and the Autism Research Program (MH073124). Funding for Dr. Scott Summers came partially from the Department of Psychiatry and Behavioral Science at the University of California-Davis.

References

- Arvio P, Arvio M. Progressive nature of aspartylglucosaminuria. *Acta Pædiatrica*. 2002; 91(3):255–257.
- Atkin JF, Flaitz K, Patil S, Smith W. A new X-linked mental retardation syndrome. *American journal of medical genetics*. 1985; 21(4):697–705. [PubMed: 4025397]
- Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. *The Journal of clinical psychiatry*. 2011; 72(2):175–182. [PubMed: 20816038]
- Brouwer JR, Willemsen R, Oostra BA. The *FMR1* gene and fragile X-associated tremor/ataxia syndrome. *American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics*. 2009; 150B(6):782–798.
- Butler MG, Pratesi R, Watson MS, Breg WR, Singh DN. Anthropometric and craniofacial patterns in mentally retarded males with emphasis on the fragile X syndrome. *Clin Genet*. 1993; 44(3):129–138. [PubMed: 8275570]
- Chonchaiya W, Au J, Schneider A, Hessl D, Harris SW, Laird M, Mu Y, Tassone F, Nguyen DV, Hagerman RJ. Increased prevalence of seizures in boys who were probands with the *FMR1* premutation and co-morbid autism spectrum disorder. *Human genetics*. 2012; 131(4):581–589. [PubMed: 22001913]
- Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST. Incidence of fragile X syndrome by newborn screening for methylated *FMR1* DNA. *American journal of human genetics*. 2009; 85(4):503–514. [PubMed: 19804849]
- Cornish KM, Kogan CS, Li L, Turk J, Jacquemont S, Hagerman RJ. Lifespan changes in working memory in fragile X premutation males. *Brain Cogn*. 2009; 69(3):551–558. [PubMed: 19114290]

- Crabbe LS, Bensky AS, Hornstein L, Schwartz DC. Cardiovascular abnormalities in children with fragile X syndrome. *Pediatrics*. 1993; 91(4):714–715. [PubMed: 8464655]
- Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. *Genetics in medicine: official journal of the American College of Medical Genetics*. 2001; 3(5):359–371. [PubMed: 11545690]
- Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. *The Journal of bone and joint surgery American volume*. 1990; 72(6):889–896. [PubMed: 2195034]
- Fisch GS. Cognitive-behavioral profiles of females with the fragile X mutation. *American journal of medical genetics Part A*. 2006; 140(7):673–677. [PubMed: 16477608]
- Gokden M, Al-Hinti JT, Harik SI. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). *Neuropathology*. 2009; 29(3):280–284. [PubMed: 18627480]
- Goodman, RM.; Gorlin, RJ. *Teh malformed infant and child*. Oxford: Oxford University Press; 1983.
- Greco CM, Soontarapornchai K, Wirojanan J, Gould JE, Hagerman PJ, Hagerman RJ. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. *J Urol*. 2007; 177(4): 1434–1437. [PubMed: 17382748]
- Grigsby J, Brega AG, Engle K, Leehey MA, Hagerman RJ, Tassone F, Hessler D, Hagerman PJ, Cogswell JB, Bennett RE, Cook K, Hall DA, Bounds LS, Paulich MJ, Reynolds A. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. *Neuropsychology*. 2008; 22(1):48–60. [PubMed: 18211155]
- Hagerman P. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. *Acta neuropathologica*. 2013; 126(1):1–19. [PubMed: 23793382]
- Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. *Current opinion in genetics & development*. 2002; 12(3):278–283. [PubMed: 12076670]
- Hunsaker MR, Greco CM, Spath MA, Smits AP, Navarro CS, Tassone F, Kros JM, Severijnen LA, Berry-Kravis EM, Berman RF, Hagerman PJ, Willemsen R, Hagerman RJ, Hukema RK. Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. *Acta neuropathologica*. 2011; 122(4):467–479. [PubMed: 21785977]
- Iwahashi C, Tassone F, Hagerman RJ, Yasui D, Parrott G, Nguyen D, Mayeur G, Hagerman PJ. A quantitative ELISA assay for the fragile x mental retardation 1 protein. *The Journal of molecular diagnostics: JMD*. 2009; 11(4):281–289. [PubMed: 19460937]
- LaFauci G, Adayev T, Kasczak R, Kasczak R, Nolin S, Mehta P, Brown WT, Dobkin C. Fragile X screening by quantification of FMRP in dried blood spots by a Luminex immunoassay. *The Journal of molecular diagnostics: JMD*. 2013; 15(4):508–517. [PubMed: 23660422]
- Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. *Neurology*. 2008; 70(16 Pt 2):1397–1402. [PubMed: 18057320]
- Loesch DZ, Godler DE, Evans A, Bui QM, Gehling F, Kotschet KE, Trost N, Storey E, Stimpson P, Kinsella G, Francis D, Thorburn DR, Venn A, Slater HR, Horne M. Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism. *Genetics in medicine: official journal of the American College of Medical Genetics*. 2011; 13(5):392–399. [PubMed: 21270637]
- Ludwig AL, Espinal GM, Pretto DI, Jamal AL, Arque G, Tassone F, Berman RF, Hagerman PJ. CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size. *Human molecular genetics*. 2014
- Marcell AV, Ellen JM. Core sexual/reproductive health care to deliver to male adolescents: perceptions of clinicians focused on male health. *The Journal of adolescent health: official publication of the Society for Adolescent Medicine*. 2012; 51(1):38–44. [PubMed: 22727075]
- Mendicino A, Sabbadini G, Pergola MS. Clark-Baraitser syndrome: report of a new case and review of the literature. *Clinical dysmorphology*. 2005; 14(3):133–135. [PubMed: 15930902]
- Merenstein SA, Sobesky WE, Taylor AK, Riddle JE, Tran HX, Hagerman RJ. Molecular-clinical correlations in males with an expanded FMR1 mutation. *American journal of medical genetics*. 1996; 64(2):388–394. [PubMed: 8844089]

- Meschede D, Behre HM, Nieschlag E. Endocrine and spermatological characteristics of 135 patients with bilateral megalotestis. *Andrologia*. 1995; 27(4):207–212. [PubMed: 7486030]
- Moore CJ, Daly EM, Schmitz N, Tassone F, Tysoe C, Hagerman RJ, Hagerman PJ, Morris RG, Murphy KC, Murphy DG. A neuropsychological investigation of male premutation carriers of fragile X syndrome. *Neuropsychologia*. 2004a; 42(14):1934–1947. [PubMed: 15381024]
- Moore CJ, Daly EM, Tassone F, Tysoe C, Schmitz N, Ng V, Chitnis X, McGuire P, Suckling J, Davies KE, Hagerman RJ, Hagerman PJ, Murphy KC, Murphy DG. The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy. *Brain*. 2004b; 127(12):2672–2681. [PubMed: 15483045]
- Myers GF, Mazzocco MM, Maddalena A, Reiss AL. No widespread psychological effect of the fragile X premutation in childhood: evidence from a preliminary controlled study. *Journal of developmental and behavioral pediatrics: JDBP*. 2001; 22(6):353–359. [PubMed: 11773799]
- Paltiel HJ, Diamond DA, Di Canzio J, Zurakowski D, Borer JG, Atala A. Testicular volume: comparison of orchidometer and US measurements in dogs. *Radiology*. 2002; 222(1):114–119. [PubMed: 11756714]
- Pretto DI, Mendoza-Morales G, Lo J, Cao R, Hadd A, Latham GJ, Durbin-Johnson B, Hagerman R, Tassone F. CGG allele size somatic mosaicism and methylation in FMR1 premutation alleles. *Journal of medical genetics*. 2014
- Saluto A, Brussino A, Tassone F, Arduino C, Cagnoli C, Pappi P, Hagerman P, Migone N, Brusco A. An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. *J Mol Diagn*. 2005; 7(5):605–612. [PubMed: 16258159]
- Schutzius G, Bleckmann D, Kapps-Fouthier S, di Giorgio F, Gerhartz B, Weiss A. A quantitative homogeneous assay for fragile X mental retardation 1 protein. *Journal of neurodevelopmental disorders*. 2013; 5(1):8. [PubMed: 23548045]
- Sreeram N, Wren C, Bhate M, Robertson P, Hunter S. Cardiac abnormalities in the fragile X syndrome. *British heart journal*. 1989; 61(3):289–291. [PubMed: 2930667]
- Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. *Seminars in reproductive medicine*. 2011; 29(4):299–307. [PubMed: 21969264]
- Tassone F, Adams J, Berry-Kravis EM, Cohen SS, Brusco A, Leehey MA, Li L, Hagerman RJ, Hagerman PJ. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). *Am J Med Genet B Neuropsychiatr Genet*. 2007; 144B(4):566–569. [PubMed: 17427188]
- Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. *American journal of human genetics*. 2000; 66(1):6–15. [PubMed: 10631132]
- Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. *Genome medicine*. 2012; 4(12):100. [PubMed: 23259642]
- Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). *RNA biology*. 2004; 1(2):103–105. [PubMed: 17179750]
- Wang JY, Hessel D, Iwahashi C, Cheung K, Schneider A, Hagerman RJ, Hagerman PJ, Rivera SM. Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles. *NeuroImage*. 2013; 65:288–298. [PubMed: 23063447]
- Wasniewska M, Matarazzo P, Weber G, Russo G, Zampolli M, Salzano G, Zirilli G, Bertelloni S. Clinical presentation of McCune-Albright syndrome in males. *Journal of pediatric endocrinology & metabolism: JPEM*. 2006; 19(Suppl 2):619–622. [PubMed: 16789625]
- Wechsler, D. *The Wechsler Adult Intelligence Scale-III: Administration and Scoring Manual*. San Antonio, TX: The Psychological Corporation; 1997.
- Zachmann M, Prader A, Kind HP, Hafliger H, Budliger H. Testicular volume during adolescence. Cross-sectional and longitudinal studies. *Helvetica paediatrica acta*. 1974; 29(1):61–72. [PubMed: 4838166]

Table 1

Descriptive statistics of study cohort

Variable	Group A Premutation with macroorchidism			Group B Premutation without macroorchidism			Group C Control without macroorchidism			P-value
	N	Mean	SD	N	Mean	SD	N	Mean	SD	
Age	46	56.35	18.6	96	57.39	16.58	67	45.36	17.54	0.0004
# of CCG Repeats	46	97	25	96	91	23	67	28	5	<.0001
<i>FMR1</i> mRNA	43	3.24	1.26	94	2.76	0.82	56	1.36	0.28	<.0001
Left Testicular Volume (ml)	46	41.52	10.01	96	23.13	6.36	47	25.47	7.2	<.0001
Right Testicular Volume (ml)	46	41.09	10.28	96	23.25	6.3	46	25.59	7.08	<.0001
Average Testicular Volume (ml)	46	41.3	10.09	96	23.19	6.24	47	25.41	7.17	<.0001
Verbal IQ	46	104.67	15.86	96	112.38	14.14	67	118.99	18.23	<.0001*
Performance IQ	46	100.46	15.64	96	105.72	15.08	67	115.4	16.93	<.0001*
Full Scale IQ	46	102.98	15.78	96	110.24	14.21	67	119.13	18.3	<.0001*

* For verbal IQ, performance IQ, and full scale IQ, after Bonferroni adjustment, both group A and group B were significantly different from group C

Table IIAssociation between macroorchidism and *FMRI* mRNA among premutation carriers

Variable	Odds Ratio	95% Confidence Interval		P-value
		Lower	Upper	
AGE	1.00	0.98	1.02	0.8318
# of CGG Repeats	0.99	0.97	1.02	0.4878
<i>FMRI</i> mRNA	1.84	1.04	3.25	0.035

* Macroorchidism status=No as reference

Table IIIa
 Association between macroorchidism and IQ, adjusted for age and CGG repeats

Variable	Least Square Mean \pm SE*			P-value	
	Group=A	Group =B	Group =C	Group	Age # of CGG Repeats
Verbal IQ	108.38 \pm 2.7	115.32 \pm 1.94	112.21 \pm 3.16	0.0481	0.3197
Performance IQ	104.7 \pm 2.64	109.26 \pm 1.9	107.41 \pm 3.09	0.2545	0.0078
Full scale IQ	107.23 \pm 2.68	113.7 \pm 1.93	111.26 \pm 3.14	0.0712	0.0042

* SE: Standard error

** Bonferroni adjusted α for entire table = 0.05/9 = 0.0056

Table IIIb
 Association between macroorchidism and IQ, adjusted for age and *FMR1* mRNA

Variable	Least Square Mean ± SE			P-value			P-value**		
	Group=A	Group =B	Group =C	Group	Age	<i>FMR1</i> /mRNA	A vs B	A vs C	B vs C
Verbal IQ	107.45 ± 2.66	113.83 ± 1.73	115.45 ± 2.75	0.0789	0.3409	0.0181	0.034	0.0638	0.6469
Performance IQ	102.99 ± 2.63	107.61 ± 1.71	111.17 ± 2.72	0.1372	0.015	0.0277	0.1198	0.0553	0.3083
Full scale IQ	105.89 ± 2.65	112.05 ± 1.72	114.91 ± 2.74	0.0659	0.0785	0.012	0.0399	0.0363	0.4181

** Bonferroni adjusted α for entire table = 0.05/9 = 0.0056